Orchestra BioMed Holdings, Inc. OBIO

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001814114

D

fourth fifth of 370 graded peers in healthcare

rank 255 of 370; percentile 68.8; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard	
Profitability	C/D percentile 59.0
Solvency	C percentile 47.8
Growth and financing	C percentile 57.4
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $114.9M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway; fortress balanc...
Inputs computable	7 of 14
Graded from	filings received through Mar 12, 2026 221 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	$5.43 2026-10-16; market equity $326.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 12, 2026

Our vision is to accelerate medical innovation to patients through risk-reward-sharing partnerships with leading medical device companies. We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development. Our business was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by our founding team.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 59.0						
Gross profitability	29.0%	32.3%		51.6	371	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(3.9%)	(6.6%)	66.5	812	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 3					
Solvency, sleeve percentile 47.8					
Twelve-month failure probability	0.10%	0.07%	58.5	247	2026-06-30
Altman Z double-prime	(7.02)	(0.30)	56.3	757	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	6.45x	2.96x	28.5	840	2025-12-31
Growth and financing, sleeve percentile 57.4					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 3					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 3					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	6.3%	2.1%	37.9	705	2025-12-31
Net share issuance, one year	52.7%	2.5%	76.8	634	2026-03-10

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 52.7%
Short runway	cash runway is 4.2 months
Fortress balance sheet	cash minus debt is 19,690,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
250	PTC Therapeutics, Inc. (PTCT)	67.5	D	
251	Amylyx Pharmaceuticals, Inc. (AMLX)	67.8	D	short runway, degenerate inputs
252	U S Physical Therapy Inc. (USPH)	68.0	D	
253	American Shared Hospital Services (AMS)	68.3	D	late filer
254	Adaptive Biotechnologies Corp. (ADPT)	68.6	D	
255	Orchestra BioMed Holdings, Inc. (OBIO)	68.8	D	dilution, short runway, fortress balance sheet
256	Iridex Corp. (IRIX)	69.1	D	fortress balance sheet
257	Lyell Immunopharma, Inc. (LYEL)	69.4	D	dilution, degenerate inputs
258	Iovance Biotherapeutics, Inc. (IOVA)	69.6	D	dilution, short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

259	Scienture Holdings, Inc. (SCNX)	69.9	D	fortress balance sheet
260	Rockwell Medical, Inc. (RMTI)	70.2	D	

What the price implies

at the 2026-10-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	103.2%	8.0%	88
Distance from 52-week high	(14.2%)	(33.0%)	74
EBIT to enterprise value	(16.1%)	(1.7%)	28
Free cash flow yield	(15.1%)	(1.0%)	26
Book value to price	0.06	0.28	20
Sales to price	0.10	0.31	25
Composite equity issuance, five years	107.8%	20.3%	79
Relative strength against the sector, log excess return	0.50	(0.13)	88

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$20.5M
Operating cash flow, four quarters	-$58.3M
Months of runway	4.2
Days since last periodic filing	70 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	$1.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:Revenues	$33.5M	2025-12-31	2026-03-12	10-K	26-026754
2	cost of revenue	us-gaap:CostOfRevenue	$190,000	2025-12-31	2026-03-12	10-K	26-026754
3	assets	us-gaap:Assets	$114.9M	2025-12-31	2026-03-12	10-K	26-026754
4	net income	us-gaap:NetIncomeLoss	-$52.7M	2025-12-31	2026-03-12	10-K	26-026754
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$49.0M	2025-12-31	2026-03-12	10-K	26-026754
6	assets	us-gaap:Assets	$76.2M	2024-12-31	2026-03-12	10-K	26-026754
7	current assets	us-gaap:AssetsCurrent	$107.9M	2025-12-31	2026-03-12	10-K	26-026754
8	current liabilities	us-gaap:LiabilitiesCurrent	$16.7M	2025-12-31	2026-03-12	10-K	26-026754
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$362.6M	2025-12-31	2026-03-12	10-K	26-026754
10	operating income	us-gaap:OperatingIncomeLoss	-$51.8M	2025-12-31	2026-03-12	10-K	26-026754
11	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$53.6M	2025-12-31	2026-03-12	10-K	26-026754
12	liabilities	us-gaap:Liabilities	$51.5M	2025-12-31	2026-03-12	10-K	26-026754
13	total debt	us-gaap:LongTermDebt	$15.0M	2025-12-31	2026-03-12	10-K	26-026754
14	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$34.7M	2025-12-31	2026-03-12	10-K	26-026754
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$327,000	2025-12-31	2026-03-12	10-K	26-026754

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

16	revenue	us-gaap:Revenues	$2.6M	2024-12-31	2026-03-12	10-K	26-026754
17	revenue	us-gaap:Revenues	$2.8M	2023-12-31	2025-03-31	10-K	25-004161
18	assets	us-gaap:Assets	$95.2M	2023-12-31	2025-03-31	10-K	25-004161
19	assets	us-gaap:Assets	$95.6M	2022-12-31	2024-03-27	10-K	24-004083
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	58,520,901	2026-03-10	2026-03-12	10-K	26-026754
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	38,312,512	2025-03-27	2025-03-31	10-K	25-004161

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.